Sodium Nitroprusside
(Synonyms: 硝普钠; Ro 21-2498) 目录号 : GC12884
硝普钠 (Ro 21-2498) 是一种有效的血管扩张剂,通过在血液中自发释放 NO 发挥作用。
Cas No.:14402-89-2
Sample solution is provided at 25 µL, 10mM.
Sodium Nitroprusside is a potent nitric oxide (NO) donor.
NO is an important cellular signaling molecule and a powerful vasodilator in the blood, thus resulting in vasodilation and increasing blood flow.
Sodium nitroprusside is a potent nitric oxide (NO) donor by releasing NO into blood. Sodium nitroprusside inhibited the contractile response of Ca2+-depleted depolarized rat aorta to extra-cellular Ca2+ and Ca2+ uptake induced by K+. Also, sodium nitroprusside decreased the rapid contraction phase induced by noradrenaline [1]. In isolated bull veins, sodium nitroprusside relaxed bull veins contraction induced by noradrenaline in a dose-dependent way [2]. In platelet-rich plasmas (PRP), sodium nitroprusside significantly inhibited platelets aggregation and also inhibited ADP and ATP release from platelets induced by collagen, which might be due to contraction of platelet smooth muscle-like protein [3].
In patients with total hip replacement under anesthesia, sodium nitroprusside (100 μg/ml) induced hypotension and reduced surgical blood loss [4].
References:
[1]. Kreye VA, Baron GD, Lüth JB, et al. Mode of action of sodium nitroprusside on vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol, 1975, 288(4): 381-402.
[2]. Gmeiner R, Riedl J, Baumgartner H. Effect of sodium nitroprusside on myocardial performance and venous tone. Eur J Pharmacol, 1975, 31(2): 287-291.
[3]. Saxon A, Kattlove HE. Platelet inhibition by sodium nitroprusside, a smooth muscle inhibitor. Blood, 1976, 47(6): 957-961.
[4]. Lawson NW, Thompson DS, Nelson CL, et al. A dosage nomogram for sodium nitroprusside-induced hypotension under anesthesia. Anesth Analg, 1976, 55(4): 574-580.
Cas No. | 14402-89-2 | SDF | |
别名 | 硝普钠; Ro 21-2498 | ||
Canonical SMILES | [C]#N.[C]#N.[C]#N.[C]#N.[C]#N.[N-]=O.[Fe-].[Na+].[Na+] | ||
分子式 | C5FeN6O.2Na | 分子量 | 261.92 |
溶解度 | ≥ 11.2mg/mL in DMSO | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.818 mL | 19.0898 mL | 38.1796 mL |
5 mM | 0.7636 mL | 3.818 mL | 7.6359 mL |
10 mM | 0.3818 mL | 1.909 mL | 3.818 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet